WXXWY - WuXi Toregem team up to develop potential tooth regeneration therapy TRG035

• WuXi Biologics ( OTCPK:WXXWY ) ( OTCPK:WXIBF ) and Toregem BioPharma tentatively formed a strategic partnership to develop monoclonal antibody TRG035 for treating congenital adentia (CA).
• CA is a genetic disorder characterized by complete or partial absence of teeth.
• Under the Memorandum of Understanding (MOU), Toregem —  a biotech startup from Japan-based Kyoto University — will have access to WuXi CMC services in cell line development, cell banking and testing, cell culture development and biologics GMP manufacturing, among other things.
• WuXi added that it will Toregem on the TRG035 project for its Investigational New Drug (IND) application ( a filing whose clearance allows a drug to enter human trials).
• "We look forward to bringing this tooth regeneration drug to the global market, treating patients across the world," said Toregem CEO Honoka Kiso.
• The company noted that a phase 1 trial of TRG035 is planned to start in early 2024.

For further details see: